Abstract
BACKGROUND
Both atrial fibrillation and chronic kidney disease increase the risk of stroke and systemic thromboembolism. However, these
risks, and the effects of antithrombotic treatment, have not been thoroughly investigated in patients with both conditions.
METHODS
Using Danish national registries, we identified all patients discharged from the hospital with a diagnosis of nonvalvular
atrial fibrillation between 1997 and 2008. The risk of stroke or systemic thromboembolism and bleeding associated with non-end-stage
chronic kidney disease and with end-stage chronic kidney disease (i.e., disease requiring renal-replacement therapy) was estimated
with the use of time-dependent Cox regression analyses. In addition, the effects of treatment with warfarin, aspirin, or both
in patients with chronic kidney disease were compared with the effects in patients with no renal disease.
RESULTS
Of 132,372 patients included in the analysis, 3587 (2.7%) had non-end-stage chronic kidney disease and 901 (0.7%) required
renal-replacement therapy at the time of inclusion. As compared with patients who did not have renal disease, patients with
non-end-stage chronic kidney disease had an increased risk of stroke or systemic thromboembolism (hazard ratio, 1.49; 95%
confidence interval [CI], 1.38 to 1.59; P<0.001), as did those requiring renal-replacement therapy (hazard ratio, 1.83; 95%
CI, 1.57 to 2.14; P<0.001); this risk was significantly decreased for both groups of patients with warfarin but not with aspirin.
The risk of bleeding was also increased among patients who had non-end-stage chronic kidney disease or required renal-replacement
therapy and was further increased with warfarin, aspirin, or both.
CONCLUSIONS
Chronic kidney disease was associated with an increased risk of stroke or systemic thromboembolism and bleeding among patients
with atrial fibrillation. Warfarin treatment was associated with a decreased risk of stroke or systemic thromboembolism among
patients with chronic kidney disease, whereas warfarin and aspirin were associated with an increased risk of bleeding. (Funded
by the Lundbeck Foundation.).
Links
Authors
Olesen JB, Lip GY, Kamper AL, Hommel K, Køber L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C
Institution
Department of Cardiology, Copenhagen University Hospital Gentofte, Hellerup, Denmark. jo@heart.dk
Source
The New England journal of medicine 367:7 2012 Aug 16 pg 625-35MeSH
AgedAspirin
Atrial Fibrillation
Female
Hematologic Agents
Hemorrhage
Humans
Kidney Failure, Chronic
Male
Myocardial Infarction
Proportional Hazards Models
Renal Insufficiency, Chronic
Renal Replacement Therapy
Risk
Stroke
Thromboembolism
Warfarin
Pub Type(s)
Journal ArticleResearch Support, Non-U.S. Gov't
Language
eng
PubMed ID
22894575
Log In

